Publications
24
Citations
74
Est. group size
~13
Recurring co-author estimate
Active years
9
Publishing since 2018
Nadeen Anabtawi's work focuses on how drugs move through and are processed by the body (pharmacokinetics), particularly transporter proteins that affect drug absorption and cancer treatment response. Recent projects examine combination therapies for cancers such as triple-negative breast cancer and blood cancers (leukemia), along with DNA repair mechanisms relevant to chemotherapy drugs like cisplatin. The work also touches on drug safety topics such as poison control reporting and pharmacy education.
Publication output has grown from occasional single papers before 2020 to a more steady pace of roughly 3 publications per year over the last five years, with some year-to-year variation.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Weaving Research and Teaching in a Course-Based Undergraduate Research Experience (CURE) Pharmaceutical Sciences Lab (Abstract ID: 229724)
Journal of Pharmacology and Experimental Therapeutics · 2026
- Metformin-Based Combination Approaches for Triple-Negative Breast Cancer
Pharmaceutics · 2025
- Pharmacokinetic Assessment of Low Dose Decitabine in Combination Therapies: Development and Validation of a Sensitive Uhplc-Ms/Ms Method for Murine Plasma Analysis
SSRN Electronic Journal · 2024
- Pharmacokinetic assessment of low dose decitabine in combination therapies: Development and validation of a sensitive UHPLC-MS/MS method for murine plasma analysis
Journal of Chromatography B · 2024
- Contribution of CNT1 and CNT3 to the intestinal transport and pharmacokinetics of decitabine
Journal of Pharmacology and Experimental Therapeutics · 2023
- The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature
Expert Opinion on Drug Metabolism & Toxicology · 2022
- Referee report. For: Factors Associated with Knowledge and Awareness of Stroke Among the Jordanian Population: A Cross-Sectional Study [version 2; peer review: 3 approved]
Faculty of 1000 Research Ltd · 2022
- Pharmacological inhibition of cryptochrome and REV-ERB promotes DNA repair and cell cycle arrest in cisplatin-treated human cells
Scientific Reports · 2021
- XPA is susceptible to proteolytic cleavage by cathepsin L during lysis of quiescent cells
DNA repair · 2021
- The impact of sarcopenia on survival among adults with hematologic malignancies: A systematic review and meta-analysis
Journal of Geriatric Oncology · 2021
- Pharmacological Inhibition of Cryptochrome and REV-ERB Promotes DNA Repair and Cell Cycle Arrest in Cisplatin-Treated Human Cells
Research Square · 2021
- Referee report. For: Factors Associated with Knowledge and Awareness of Stroke Among the Jordanian Population: A Cross-Sectional Study [version 1; peer review: 1 approved]
Faculty of 1000 Research Ltd · 2021
- A descriptive analysis of home-based therapeutic errors reported to a recently opened poison center
Journal of Emergency Medicine · 2020
- Energy drink warning label compliance with Qatar law
Journal of Emergency Medicine · 2020
- 1451: PREDICTORS OF AUGMENTED RENAL CLEARANCE IN CRITICALLY ILL PATIENTS WITH CANCER
Critical Care Medicine · 2018
- Journal of Pharmacology and Experimental Therapeutics×4
- Nature Communications×2
- Journal of Emergency Medicine×2
- Faculty of 1000 Research Ltd×2
- Expert Opinion on Drug Metabolism & Toxicology×1
- Ruchika Raj
Medicine · The Ohio State University
- Yosra Ben Youssef
Medicine · The Ohio State University
- C. D. Bloomfield
Medicine · The Ohio State University
- Jessica Kohlschmidt
Medicine · The Ohio State University
- Kieran Sahasrabudhe
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile